Nezavist

Nezavist
Clinical data
Other namesDCUK-OEt; DCUKA ethyl ester; DCUK ethyl carboxylate
Routes of
administration
Oral
Drug classPeripherally selective GABAA receptor positive allosteric modulator
Identifiers
  • ethyl 5,7-dichloro-4-(diphenylcarbamoylamino)quinoline-2-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H19Cl2N3O3
Molar mass480.35 g·mol−1
3D model (JSmol)
  • CCOC(=O)C1=NC2=C(C(=C1)NC(=O)N(C3=CC=CC=C3)C4=CC=CC=C4)C(=CC(=C2)Cl)Cl
  • InChI=1S/C25H19Cl2N3O3/c1-2-33-24(31)22-15-21(23-19(27)13-16(26)14-20(23)28-22)29-25(32)30(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-15H,2H2,1H3,(H,28,29,32)
  • Key:UHTVXLVKFPJKMP-UHFFFAOYSA-N

Nezavist, also known as DCUK-OEt, is a peripherally selective GABAA receptor positive allosteric modulator which is under development for the treatment of alcoholism and depressive disorders. It is taken orally. The drug is a positive allosteric modulator (PAM) specifically of the etomidate allosteric site of the GABAA receptor. As it does not cross the blood–brain barrier, Nezavist is peripherally selective and does not directly produce central nervous system effects. Nonetheless, the drug has been found to reduce alcohol self-administration in rodents, perhaps via intestinal stimulation of the vagus nerve. Nezavist is under development by Lohocla Research. As of October 2025, it is in phase 1 clinical trials for alcoholism and the preclinical research stage of development for depressive disorders.

See also